Effect of Metformin Combined with Atorvastatin on Glucose Metabolism in Schizophrenia Patients with Dyslipidemia

What this Trial Is About

Schizophrenia is a serious mental disorder linked to significant disability and health risks, including metabolic side effects like weight gain and dyslipidemia caused by antipsychotic medications. This trial investigates how atorvastatin, a cholesterol-lowering drug, affects glucose metabolism in patients with schizophrenia who have dyslipidemia, and whether metformin can help improve these metabolic issues. Researchers aim to understand the impact of statins on blood sugar and insulin resistance and explore metformins potential benefits for these patients. Participants will be randomly assigned to two groups one receiving atorvastatin 20 mg daily combined with metformin 1000 mg daily, and the other receiving atorvastatin 20 mg daily with a placebo that looks like metformin. The study lasts six months, with follow-up assessments at three and six months. During this time, patients will take their assigned medications daily, and researchers will monitor their glucose metabolism and lipid levels. Participants will undergo blood tests at baseline, three months, and six months to measure fasting blood glucose, glycated hemoglobin, insulin levels, and lipid profiles. Additional assessments include oral glucose tolerance tests, abdominal ultrasound, and mental health evaluations using standardized scales. The study monitors changes in glucose metabolism and schizophrenia symptoms while tracking safety and treatment adherence over six months.

Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients